Figures below are as of 21 Jul 2026. GMP is an unofficial, unregulated indicator of grey-market demand and is not investment advice.
| Grey Market Premium (GMP) | ₹112 |
| Estimated listing gain | +32.7% |
| Estimated listing price | ₹455 |
| Issue price | ₹343 |
| Issue size | ₹214.48 Cr |
| Subscription | 102.42x |
| Open date | 21 May 2026 |
| Close date | 25 May 2026 |
| Listing date | 29 May 2026 |
| Listing at | NSE SME |
| IPO type | SME |
| Registrar | Purva Sharegistry (India) Pvt.Ltd. |
As of 21 Jul 2026, the grey market premium (GMP) for the Q-Line Biotech Ltd. IPO is ₹112, implying an estimated listing gain of about +32.7% and an estimated listing price near ₹455. GMP is unofficial and unregulated — it indicates grey-market sentiment, not a guaranteed listing price.
The Q-Line Biotech Ltd. IPO is open for subscription from 21 May 2026 to 25 May 2026. It is expected to list on 29 May 2026.
The Q-Line Biotech Ltd. IPO is priced at ₹343 per share, with a total issue size of ₹214.48 Cr.
As of 21 Jul 2026, the Q-Line Biotech Ltd. IPO is subscribed 102.42x.